Novo Nordisk’s investment of more than half a billion dollars is meant to expand its production capabilities in China and help it meet the global drug demand.
Tag Archive for: drug manufacturing
A company executive stated that Gilead will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech’s manufacturing processes.
With the investment in the plant, Daiichi Sankyo is looking to create new laboratories for its antibody drug conjugates used to develop and manufacture therapies for breast, lung and stomach cancers.
With drug shortages in the U.S. not greatly improving, the Federal Trade Commission and the Department of Health and Human Services announced Wednesday that they are issuing a request for information to look at different groups involved in generic drug supply chains and evaluate how they may be contributing to persistent shortages.
BioNTech is making moves in early 2024 to strengthen its CAR T pipeline, with a $250 million licensing and manufacturing deal announced Thursday with Autolus Therapeutics to advance the companies’ respective programs.
The company said it is already making manufacturing investments for orforglipron, its next-generation oral weight-loss candidate that recently moved into Phase III development.
The new facility in Rockville, Maryland will focus on manufacturing for critical cancer trials and launch of its commercial cell therapy platforms.
“We are very pleased with the agreement to acquire the three Catalent manufacturing sites which will enable us to serve significantly more people living with diabetes and obesity in the future,“ said Lars Fruergaard Jørgensen, president and chief executive officer at Novo Nordisk.
Citing America’s Poison Centers, which represents 55 regional poison centers across the U.S., Reuters revealed that all three incidences of hypoglycemia were detected by the same regional poison control center and that the FDA was investigating these reports.
U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly (LLY.N) plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters.